Tailoring breast cancer screening intervals by breast density and risk for women aged 50 years or older: Collaborative modeling of screening outcomes

Annals of Internal Medicine

Volumn 165, Issue 10, 2016, Pages 700-712

  Trentham Dietz, Amy ^a   Kerlikowske, Karla ^b   Stout, Natasha K ^c   Miglioretti, Diana L ^d   Schechter, Clyde B ^e   Ergun, Mehmet Ali ^f   Van Den Broek, Jeroen J ^g   Alagoz, Oguzhan ^f   Sprague, Brian L ^h   Van Ravesteyn, Nicolien T ^g   Near, Aimee M ⁱ   Gangnon, Ronald E ^j   Hampton, John M ^a   Chandler, Young ⁱ   De Koning, Harry J ^g   Mandelblatt, Jeanne S ⁱ   Tosteson, Anna N A ^k  

^a UNIVERSITY OF WISCONSIN   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f University of Wisconsin Madison   (United States)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF VERMONT   (United States)

ⁱ GEORGETOWN UNIVERSITY   (United States)

^j UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^k DARTMOUTH MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST DENSITY; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; FALSE POSITIVE RESULT; FEMALE; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; SIMULATION; UNITED STATES; ADVERSE EFFECTS; BREAST TUMOR; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; DIAGNOSTIC IMAGING; EARLY CANCER DIAGNOSIS; ECONOMICS; EPIDEMIOLOGY; HEALTH SERVICE; MASS SCREENING; MORTALITY; PROCEDURES; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR;

AGED; BREAST DENSITY; BREAST NEOPLASMS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; LIFE EXPECTANCY; MAMMOGRAPHY; MASS SCREENING; MEDICAL OVERUSE; MIDDLE AGED; MODELS, STATISTICAL; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 84995899174     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M16-0476     Document Type: Article

References (57)

1. Kerlikowske K. Progress toward consensus on breast cancer screening guidelines and reducing screening harms. JAMA Intern Med. 2015;175:1970-1. [PMID: 26502319] doi:10.1001/jamaintern med.2015.6466
2. Siu AL, Bibbins-Domingo K, Grossman DC, LeFevre ML; U.S. Preventive Services Task Force. Convergence and divergence around breast cancer screening [Editorial]. Ann Intern Med. 2016;164:301-2. [PMID: 26756136] doi:10.7326/M15-3065
3. Siu AL; U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2016;164:279-96. [PMID: 26757170] doi:10 .7326/M15-2886
4. Oeffinger KC, Fontham ET, Etzioni R, Herzig A, Michaelson JS, Shih YC, et al; American Cancer Society. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA. 2015;314:1599-614. [PMID: 26501536] doi: 10.1001/jama.2015.12783
5. Myers ER, Moorman P, Gierisch JM, Havrilesky LJ, Grimm LJ, Ghate S, et al. Benefits and harms of breast cancer screening: a systematic review. JAMA. 2015;314:1615-34. [PMID: 26501537] doi:10 .1001/jama.2015.13183
6. Nelson HD, Pappas M, Cantor A, Griffin J, Daeges M, Humphrey L. Harms of breast cancer screening: systematic review to update the 2009 U.S. Preventive Services Task Force recommendation. Ann Intern Med. 2016;164:256-67. [PMID: 26756737] doi:10.7326/M15-0970
7. Lauby-Secretan B, Scoccianti C, Loomis D, Benbrahim-Tallaa L, Bouvard V, Bianchini F, et al; International Agency for Research on Cancer Handbook Working Group. Breast-cancer screening-viewpoint of the IARC Working Group. N Engl J Med. 2015;372:2353-8. [PMID: 26039523] doi:10.1056/NEJMsr1504363
8. Mandelblatt JS, Stout NK, Schechter CB, van den Broek JJ, Miglioretti DL, Krapcho M, et al. Collaborative modeling of the benefits and harms associated with different U.S. breast cancer screening strategies. Ann Intern Med. 2016;164:215-25. [PMID: 26756606] doi:10.7326/M15-1536
9. Kerlikowske K, Zhu W, Hubbard RA, Geller B, Dittus K, Braithwaite D, et al; Breast Cancer Surveillance Consortium. Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy. JAMA Intern Med. 2013;173:807-16. [PMID: 23552817] doi:10.1001/jamainternmed.2013.307
10. Vilaprinyo E, Forné C, Carles M, Sala M, Pla R, Castells X, et al; Interval Cancer (INCA) Study Group. Cost-effectiveness and harmbenefit analyses of risk-based screening strategies for breast cancer. PLoS One. 2014;9:e86858. [PMID: 24498285] doi:10.1371/journal .pone.0086858
11. Schousboe JT, Kerlikowske K, Loh A, Cummings SR. Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med. 2011;155:10-20. [PMID: 21727289] doi:10.7326/0003-4819-155-1-201107050-00003
12. Kerlikowske K, Zhu W, Tosteson AN, Sprague BL, Tice JA, Lehman CD, et al; Breast Cancer Surveillance Consortium. Identifying women with dense breasts at high risk for interval cancer: a cohort study. Ann Intern Med. 2015;162:673-81. [PMID: 25984843] doi:10 .7326/M14-1465
13. van Ravesteyn NT, Miglioretti DL, Stout NK, Lee SJ, Schechter CB, Buist DS, et al. Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk. Ann Intern Med. 2012;156:609-17. [PMID: 22547470] doi:10.7326/0003-4819-156-9-201205010-00002
14. Mandelblatt J, Cronin KA, de Koning H, Miglioretti DL, Schechter C, Stout N, et al. Collaborative Modeling of U.S. Breast Cancer Screening Strategies. AHRQ publication no. 14-05201-EF-4. Rockville, MD: Agency for Healthcare Research and Quality; 2015.
15. National Cancer Institute. Breast Cancer Surveillance Consortium. 6 July 2015. Accessed at http://breastscreening.cancer.gov on 17 May 2016.
16. American College of Radiology. The American College of Radiology Breast Imaging Reporting and Data System (BI-RADS). 4th ed. Reston, VA: American College of Radiology; 2003.
17. Munsell MF, Sprague BL, Berry DA, Chisholm G, Trentham-Dietz A. Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiol Rev. 2014;36:114-36. [PMID: 24375928] doi:10.1093/epirev/mxt010
18. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-Analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13:1141-51. [PMID: 23084519] doi:10.1016/S1470-2045(12)70425-4
19. Hamajima N, Hirose K, Tajima K, Rohan T, Calle EE, HeathCWJr, et al; Collaborative Group on Hormonal Factors in Breast Cancer. Alcohol, tobacco and breast cancer-collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer. 2002;87:1234-45. [PMID: 12439712]
20. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Alcohol Consumption and Ethyl Carbamate. Lyon, France: World Health Organization; 2010.
21. Chlebowski RT, Anderson GL, Aragaki AK, Prentice R. Breast cancer and menopausal hormone therapy by race/ethnicity and body mass index. J Natl Cancer Inst. 2016;108. [PMID: 26546117] doi:10.1093/jnci/djv327
22. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, et al; WHI Investigators. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA.2010;304:1684-92. [PMID: 20959578] doi:10.1001/jama.2010 .1500
23. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288: 321-33. [PMID: 12117397]
24. Trentham-Dietz A, Sprague BL, Hampton JM, Miglioretti DL, Nelson HD, Titus LJ, et al. Modification of breast cancer risk according to age and menopausal status: a combined analysis of five populationbased case-control studies. Breast Cancer Res Treat. 2014;145:165-75. [PMID: 24647890] doi:10.1007/s10549-014-2905-y
25. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001;358: 1389-99. [PMID: 11705483]
26. Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: a systematic review and metaanalysis. Int J Cancer. 1997;71:800-9. [PMID: 9180149]
27. Tice JA, Miglioretti DL, Li CS, Vachon CM, Gard CC, Kerlikowske K. Breast density and benign breast disease: risk assessment to identify women at high risk of breast cancer. J Clin Oncol. 2015;33:3137-43. [PMID: 26282663] doi:10.1200/JCO.2015.60.8869
28. Dyrstad SW, Yan Y, Fowler AM, Colditz GA. Breast cancer risk associated with benign breast disease: systematic review and metaanalysis. Breast Cancer Res Treat. 2015;149:569-75. [PMID: 25636589] doi:10.1007/s10549-014-3254-6
29. Mavaddat N, Pharoah PD, Michailidou K, Tyrer J, Brook MN, Bolla MK, et al. Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst. 2015;107. [PMID: 25855707] doi:10.1093/jnci/djv036
30. Munoz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O, et al. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. J Natl Cancer Inst. 2014; 106. [PMID: 25255803] doi:10.1093/jnci/dju289
31. Gangnon RE, Sprague BL, Stout NK, Alagoz O, Weedon-Fekjaer H, Holford TR, et al. The contribution of mammography screening to breast cancer incidence trends in the United States: an updated ageperiod-cohort model. Cancer Epidemiol Biomarkers Prev. 2015;24: 905-12. [PMID: 25787716] doi:10.1158/1055-9965.EPI-14-1286
32. Carter SB, Gartner SS, Haines MR, Olmstead AL, Sutch R, Wright G. Historical Statistics of the United States, Volume One: Population. New York: Cambridge Univ Pr; 2006.
33. Fryback DG, Stout NK, Rosenberg MA, Trentham-Dietz A, Kuruchittham V, Remington PL. The Wisconsin Breast Cancer Epidemiology Simulation Model. J Natl Cancer Inst Monogr. 2006:37-47. [PMID: 17032893]
34. Mandelblatt J, Schechter CB, Lawrence W, Yi B, Cullen J. The SPECTRUM population model of the impact of screening and treatment on U.S. breast cancer trends from 1975 to 2000: principles and practice of the model methods. J Natl Cancer Inst Monogr. 2006:47-55. [PMID: 17032894]
35. Tan SY, van Oortmarssen GJ, de Koning HJ, Boer R, Habbema JD. The MISCAN-Fadia continuous tumor growth model for breast cancer. J Natl Cancer Inst Monogr. 2006:56-65. [PMID: 17032895]
36. Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O'Meara ES, et al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-Analysis. Ann Intern Med. 2012;156: 635-48. [PMID: 22547473] doi:10.7326/0003-4819-156-9-2012 05010-00006
37. Cronin KA, Mariotto AB, Clarke LD, Feuer EJ. Additional common inputs for analyzing impact of adjuvant therapy and mammography on U.S. mortality. J Natl Cancer Inst Monogr. 2006:26-9. [PMID: 17032891]
38. Cronin KA, Yu B, Krapcho M, Miglioretti DL, Fay MP, Izmirlian G, et al. Modeling the dissemination of mammography in the United States. Cancer Causes Control. 2005;16:701-12. [PMID: 16049809]
39. Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, et al; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-Analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379:432-44. [PMID: 22152853] doi:10.1016/S0140-6736(11)61625-5
40. Mariotto AB, Feuer EJ, Harlan LC, Abrams J. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. J Natl Cancer Inst Monogr. 2006:7-15. [PMID: 17032888]
41. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer. 2015. Accessed at www .nccn.org/professionals/physician-gls/f-guidelines.asp on 1 August 2016.
42. Stout NK, Lee SJ, Schechter CB, Kerlikowske K, Alagoz O, Berry D, et al. Benefits, harms, and costs for breast cancer screening after U.S. implementation of digital mammography. J Natl Cancer Inst. 2014;106:dju092. [PMID: 24872543] doi:10.1093/jnci/dju092
43. Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008;100:630-41. [PMID: 18445825] doi: 10.1093/jnci/djn103
44. de Haes JC, de Koning HJ, van Oortmarssen GJ, van Agt HM, de Bruyn AE, van Der Maas PJ. The impact of a breast cancer screening programme on quality-Adjusted life-years. Int J Cancer. 1991;49: 538-44. [PMID: 1917155]
45. Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG. Report of nationally representative values for the noninstitutionalized U.S. adult population for 7 health-related quality-of-life scores. Med Decis Making. 2006;26:391-400. [PMID: 16855127]
46. Stout NK, Rosenberg MA, Trentham-Dietz A, Smith MA, Robinson SM, Fryback DG. Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer Inst. 2006;98:774-82. [PMID: 16757702]
47. National Cancer Institute. Surveillance Epidemiology and End Results Program. SEER Stat Database: Incidence-SEER 9 Regs Research Data, Nov 2014 Sub (1973-2012)-Linked to County Attributes-Total U.S., 1969-2013 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch. April 2015 (based on the November 2014 submission). Accessed at www.seer.cancer.gov on 1 August 2016.
48. Sprague BL, Gangnon RE, Burt V, Trentham-Dietz A, Hampton JM, Wellman RD, et al. Prevalence of mammographically dense breasts in the United States. J Natl Cancer Inst. 2014;106. [PMID: 25217577] doi:10.1093/jnci/dju255
49. Rosenberg RD, Yankaskas BC, Abraham LA, Sickles EA, Lehman CD, Geller BM, et al. Performance benchmarks for screening mammography. Radiology. 2006;241:55-66. [PMID: 16990671]
50. van Ravesteyn NT, Stout NK, Schechter CB, Heijnsdijk EA, Alagoz O, Trentham-Dietz A, et al. Benefits and harms of mammography screening after age 74 years: model estimates of overdiagnosis. J Natl Cancer Inst. 2015;107. [PMID: 25948872] doi:10.1093/jnci/djv103
51. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness-the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371:796-7. [PMID: 25162885] doi:10.1056/NEJMp1405158
52. Giordano L, von Karsa L, Tomatis M, Majek O, de Wolf C, Lancucki L, et al; Eunice Working Group. Mammographic screening programmes in Europe: organization, coverage and participation. J Med Screen. 2012;19 Suppl 1:72-82. [PMID: 22972813]
53. von Karsa L, Antilla A, Ronco G, Ponti A, Malila N, Arbyn M, et al. Cancer Screening in the European Union: Report on the Implementation of the Council Recommendation on Cancer Screening. First Report. Luxembourg City, Luxembourg: European Communities; 2008.
54. Lansdorp-Vogelaar I, Gulati R, Mariotto AB, Schechter CB, de Carvalho TM, Knudsen AB, et al. Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. Ann Intern Med. 2014;161:104-12. [PMID: 25023249] doi:10.7326/M13-2867
55. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879-86. [PMID: 2593165]
56. Rosner B, Colditz GA. Nurses' health study: log-incidence mathematical model of breast cancer incidence. J Natl Cancer Inst. 1996; 88:359-64. [PMID: 8609645]
57. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23: 1111-30. [PMID: 15057881]